ImmunityBio, Inc. is a clinical-stage biotechnology company developing therapies and vaccines to enhance the immune system against cancers and infectious diseases. It uses proprietary platforms to activate both the innate and adaptive immune systems, targeting cancer and pathogens. These platforms include antibody-cytokine fusion proteins, DNA, RNA, and recombinant protein vaccines, and cell therapies. Its lead product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein designed to boost immune response. ImmunityBio aims to orchestrate a comprehensive immune attack on cancer and infectious diseases through its innovative therapies. The IBRX average annual return since 2015 is shown above.
The Average Annual Return on the IBRX average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether IBRX average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the IBRX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free IBRX Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
